Clinical trial
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once…
NCT00443053 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00443053 |
|---|---|
| Title | Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis) |
| Official title | An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5mg Subcutaneously) for the Treatment of Patients With Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thrombosis, Venous |
| Intervention type | Drug |
| Interventions | Fondaparinux 2.5mg or placebo |
| Enrollment | 3,002 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 6, 2017 |
| Countries | Bulgaria, Czechia, Estonia, France, Germany, Greece, Hungary, Israel, Italy, Latvia, Netherlands, Poland and 5 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: